Arbutus Biopharma (ABUS) vs Corvus Pharmaceuticals (CRVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Corvus Pharmaceuticals (CRVS) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 51.5% versus a gain of 0.0%. Over five years, CRVS leads with a +110.3% price change compared with +5.1% for ABUS. Corvus Pharmaceuticals is the larger company by market cap ($875.7 million vs $657.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | CRVS |
|---|---|---|
| Share price | $4.29 | $10.41 |
| Market cap | $657.55M | $875.70M |
| 1-day change | -4.24% | -1.42% |
| YTD return | -10.81% | +35.19% |
| 1-year return | 0.00% | +51.53% |
| 5-year return | +5.15% | +110.30% |
| P/E ratio (TTM) | 5.43 | — |
| EPS (TTM) | $0.79 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $26.95 |
| 52-week low | $3.50 | $6.39 |
| Distance from 52-week high | -21.28% | -61.37% |
| Average volume | 4.65M | 996.12K |
| Shares outstanding | 153.28M | 84.12M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVS has outperformed ABUS by 51.5 percentage points over the past year.
ABUS vs CRVS FAQ
Which is bigger, Arbutus Biopharma or Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) is larger, with a market capitalization of $875.70M compared with $657.55M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or CRVS?
CRVS returned +51.53% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Corvus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.